← All trials
NCT05307705
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 11, 2022
- Primary completion
- May 31, 2025
- Completion date
- May 31, 2025
- First posted
- Apr 1, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 300
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Eli LillyLead sponsor
- Loxo OncologyCollaborator
- Loxo OncologyStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.